2021
DOI: 10.1111/ijd.15467
|View full text |Cite
|
Sign up to set email alerts
|

COVID‐19 and biologic therapies in dermatology: seroprevalence survey and severity analysis in a tertiary hospital in Spain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 4 publications
1
2
0
Order By: Relevance
“…The selfreported data being similar to the seroprevalence indicate a strong awareness of SARS-CoV-2 infection in these patients (1,18). Barrutia et al observed that seroprevalence of SARS-CoV-2 in patients with psoriasis was in line with that of the general population (4.1% vs. 4.4%) (19). Another study by Yendo et al found that the seroprevalence of SARS-CoV-2 in their cohort of patients with psoriasis of biologic therapy in Sao Paolo was higher than that in the general population (32% vs. 11%) (20).…”
Section: Course and Severity Of Sars-cov-2 In Patients With Psoriasis...supporting
confidence: 57%
See 1 more Smart Citation
“…The selfreported data being similar to the seroprevalence indicate a strong awareness of SARS-CoV-2 infection in these patients (1,18). Barrutia et al observed that seroprevalence of SARS-CoV-2 in patients with psoriasis was in line with that of the general population (4.1% vs. 4.4%) (19). Another study by Yendo et al found that the seroprevalence of SARS-CoV-2 in their cohort of patients with psoriasis of biologic therapy in Sao Paolo was higher than that in the general population (32% vs. 11%) (20).…”
Section: Course and Severity Of Sars-cov-2 In Patients With Psoriasis...supporting
confidence: 57%
“…Barrutia et al. observed that seroprevalence of SARS-CoV-2 in patients with psoriasis was in line with that of the general population (4.1% vs. 4.4%) ( 19 ). Another study by Yendo et al.…”
Section: Resultsmentioning
confidence: 74%
“… 3 Another study, which was done in Spain, did not show increase risk of COVID‐19 infection in these patients. 7 Additionally, methotrexate therapy was not associated with increased risk of hospitalization. 8 , 9 We did not find any significant difference in COVID‐19 infection rate between psoriatic patients receiving biologic therapy and non‐biologic immunosuppressive and also non‐immunosuppressive drugs.…”
Section: Tablementioning
confidence: 95%